

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **INSIDE INFORMATION POSSIBLE ESTABLISHMENT OF KOREAN DEPOSITARY RECEIPT PROGRAMME ON THE KOREA EXCHANGE**

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board announces that the Company is exploring for a KDR Programme on the Korea Exchange. The Company, through its legal adviser in Korea and the Lead Manager, is in discussion with the Korea Exchange regarding the proposed KDR Programme. As at the date of this announcement, no application relating to the KDR Programme has been made to the Korea Exchange.

Shareholders should note that the proposed KDR Programme may or may not proceed. In the event that the proposed KDR Programme proceeds and the Company becomes subject to any reporting, shareholders' approval and/or other requirements under the Listing Rules, any applicable laws and regulations or the memorandum and articles of association of the Company due to the transactions contemplated under the proposed KDR Programme, the Company will comply with the relevant reporting, shareholders' approval and/or other requirements as and when appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) ("**SFO**").

The board of directors (the “**Board**”) of Essex Bio-Technology Limited (the “**Company**”) announces that the Company is exploring for a Korean Depository Receipt Programme (the “**KDR Programme**”) on the Korea Exchange. The Company has appointed Daishin Securities Co., Ltd. (the “**Lead Manager**”), headquartered in Seoul, Korea, as the lead manager to advise on the proposed KDR Programme. The Company, through its legal adviser in Korea and the Lead Manager, is in discussion with the Korea Exchange regarding the proposed KDR Programme. As at the date of this announcement, no application relating to the KDR Programme has been made to the Korea Exchange.

The Company and its subsidiaries are principally engaged in the manufacturing, selling, marketing and distribution of biopharmaceutical products. The Board considers that it is highly attractive to pursue a Depository Receipt Programme in Korea, since the listing of pharmaceutical or biotechnology companies on the Korea Exchange continues to gain momentum in recent years. Furthermore, the Board believes that the KDR Programme will serve as an attractive alternative for international investors, in particular, potential investors in Korea, to invest and deal in the shares of the Company and will (i) provide further liquidity for the Company’s shares; (ii) increase awareness of the Company; (iii) promote the Company’s corporate image and potential strategic alliances; and (iv) broaden the shareholder base of the Company. As such, the Board considers that the proposed establishment of the KDR Programme, in the event that it proceeds, will be in the interests of the Company and its shareholders (“**Shareholders**”) as a whole.

Shareholders should note that the proposed KDR Programme may or may not proceed. In the event that the proposed KDR Programme proceeds and the Company becomes subject to any reporting, shareholders’ approval and/or other requirements under the Listing Rules, any applicable laws and regulations or the memorandum and articles of association of the Company due to the transactions contemplated under the proposed KDR Programme, the Company will comply with the relevant reporting, shareholders’ approval and/or other requirements as and when appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 8 March 2017

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*